Administration of the compound
triterpene 3β, 6β, 16β-trihidroxilup-20(29)-ene (TTHL) resulted in antinociceptive activity in several
pain models in mice. Because
pain and
epilepsy have common mechanisms, and several
anticonvulsants are clinically used to treat painful disorders, we investigated the
anticonvulsant potential of TTHL. Behavioral and electrographic recordings revealed that pretreatment with TTHL (30 mg/kg; i.g.) increased the latencies to the first clonic seizure to the tonic-clonic and reduced the duration of the
generalized seizures induced by the
GABA(A) receptor antagonist PTZ (80 g; i.p.). The TTHL pretreatment also protected against PTZ-induced deleterious effects, as characterized by protein carbonylation, lipid peroxidation, [(3)H]
glutamate uptake and the inhibition of Na(+),K(+)-
ATPase (subunits α(1) and α(2)/α(3)). Although TTHL did not exhibit DPPH,
ABTS radical scavenging activity per se and does not alter the binding of [(3)H]
flunitrazepam to the benzodiazepinic site of the
GABA(A) receptor, this compound was effective in preventing behavioral and EEG
seizures, as well as the inhibition of Na(+),K(+)-
ATPase induced by
ouabain. These results suggest that the protection against PTZ-induced
seizures elicited by TTHL is due to Na(+),K(+)-
ATPase activity maintenance. In fact, experiments in homogenates of the cerebral cortex revealed that PTZ (10 mM) reduced Na(+),K(+)-
ATPase activity and that previous incubation with TTHL (10 μM) protected against this inhibition. Collectively, these data indicate that the protection exerted by TTHL in this model of convulsion is not related to
antioxidant activity or GABAergic activity. However, these results demonstrated that the effective protection of Na(+),K(+)-
ATPase elicited by this compound protects against the damage due to neuronal excitability and oxidation that is induced by PTZ.